Android app on Google Play

OPKO Health (OPK) Licenses Alzheimer's Disease IP to Lab Corp (LH)

April 3, 2012 8:58 AM EDT Send to a Friend
Get Alerts OPK Hot Sheet
Trade OPK Now!
Join SI Premium – FREE
OPKO Health, Inc. (NYSE: OPK) has signed an agreement with Laboratory Corporation of America Holdings (NYSE: LH) under which LabCorp licensed exclusive rights in North America and the United Arab Emirates to OPKO’s intellectual property to develop and commercialize laboratory testing services for Alzheimer’s disease. Financial terms of the transaction were not disclosed.

OPKO’s diagnostic is designed to detect elevated levels of antibodies that appear to be unique to Alzheimer’s disease. The Alzheimer’s disease-specific antibodies were discovered using OPKO’s novel proprietary platform that OPKO has demonstrated in initial studies to be capable of identifying biomarkers for a wide range of diseases to which the immune system reacts, including Alzheimer’s disease, as well as cancers, autoimmune diseases, neurodegenerative diseases and infectious diseases. In addition to Alzheimer’s disease, OPKO is pursuing the development of diagnostics for non-small cell lung cancer, pancreatic and other cancers, and diseases for which early detection could lead to earlier therapy and dramatically improved outcomes.




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment